Eli Lilly and Company today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), olomorasib, an investigational KRAS G12C inhibitor, ...

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 ...

The global market for peptide-based cancer therapies is rapidly expanding, offering new therapeutic and diagnostic opportunities. Peptides, known for their high specificity and minimized toxicity, ...

Genmab A/S (Nasdaq: GMAB) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical ...

A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment in the phase 1 PMB-102 trial.

With its commitment to comprehensive, patient-centered care, OrthoCarolina continues to transform patient lives through world-class orthopedic treatment and musculoskeletal expertise. A powerful ...

BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Lt ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...

Researchers from the lab led by Prof. Joris De Wit (VIB-KU Leuven) have discovered an important clue to how connections ...